Alterations to the structure of Leishmania major induced by N-arylisoquinolines correlate with compound accumulation and disposition

References

1. Bandyopadhyay P., Ghosh D. K., De A., Ghosh K. N., Chaudhuri P. P., Das P., Bhattacharya A. 1991; Metacyclogenesis of Leishmania spp : species-specific in vitro transformation, complement resistance, and cell surface carbohydrate and protein profiles. J Parasitol 77:411–446
   [Google Scholar]
2. Bera A., Singh S., Nagaraj R., Vaidya T. 2003; Induction of autophagic cell death in Leishmania donovani by antimicrobial peptides. Mol Biochem Parasitol 127:23–35 [CrossRef]
   [Google Scholar]
3. Berger B. J., Fairlamb A. H., Meiering S. K., Schmidt H. 1993; Cytochrome P450 in trypanosomatids. Biochem Pharmacol 46:149–157
   [Google Scholar]
4. Bringmann G., Pokorny F. 1995; The naphthylisoquinoline alkaloids. In The Alkaloids vol 46 pp 127–271 Edited by Cordell G. A. New York: Academic Press;
   [Google Scholar]
5. Bringmann G., François G., Aké Assi L., Schlauer J. 1998; The alkaloids of Triphyophyllum peltatum (Dioncophyllaceae. Chimia (Aarau 52:18–28
   [Google Scholar]
6. Bringmann G., Hamm A., Günther C., Michel M., Brun R., Mudogo V. 2000; Ancistroealaines A and B, two new bioactive naphthylisoquinolines, and related naphthoic acids from Ancistrocladus ealaensis . J Nat Prod 63:1465–1470 [CrossRef]
   [Google Scholar]
7. Bringmann G., Dreyer M., Faber J. H., Dalsgaard P. W., Staerk D., Jaroszewski J. W., Ndangalasi H., Mbago F., Brun R. other authors 2003a; Ancistrotanzanine A, the first 5,3′-coupled naphthylisoquinoline alkaloid, and two further, 5,8′-linked related compounds from the newly described species Ancistrocladus tanzaniensis . J Nat Prod 66:1159–1165 [CrossRef]
   [Google Scholar]
8. Bringmann G., Hoerr V., Holzgrabe U., Stich A. 2003b; Antitrypanosomal naphthylisoquinoline alkaloids and related compounds. Pharmazie 58:343–346
   [Google Scholar]
9. Bringmann G., Kajahn I., Pedersen S. E. H., Faber J. H., Reichert M., Gulder T., Brun R., Christensen S. B., Ponte-Sucre A. other authors 2006; Ancistrocladinium A and B, the first N,C -coupled naphthyldihydroisoquinoline alkaloids, from a Congolese Ancistrocladus species. J Org Chem 71:9348–9356 [CrossRef]
   [Google Scholar]
10. Chappuis F., Sundar S., Hailu A., Ghalib H., Rijal S., Peeling R. W., Alvar J., Boelaert M. 2007; Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?. Nat Rev Microbiol 5:873–882
    [Google Scholar]
11. Croft S. L. 2008; Kinetoplastida: new therapeutic strategies. Parasite 15:522–527 [CrossRef]
    [Google Scholar]
12. Croft S. L., Seifert K., Yardley V. 2006; Current scenario of drug development for leishmaniasis. Indian J Med Res 123:399–410
    [Google Scholar]
13. Davis A. J., Murray H. W., Handman E. 2004; Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol 20:73–76 [CrossRef]
    [Google Scholar]
14. Dodge M. A., Waller R. F., Chow L. M., Zaman M. M., Cotton L. M., McConville M. J., Wirth D. F. 2004; Localization and activity of multidrug resistance protein 1 in the secretory pathway of Leishmania parasites. Mol Microbiol 51:1563–1575 [CrossRef]
    [Google Scholar]
15. François G., Timperman G., Holenz J., Aké Assi L., Geuder T., Maes L., Dubois J., Hanocq M., Bringmann G. 1996; Naphthylisoquinoline alkaloids exhibit strong growth-inhibiting activities against Plasmodium falciparum and P. berghei in vitro – structure-activity relationships of dioncophylline C. Ann Trop Med Parasitol 90:115–123
    [Google Scholar]
16. François G., Timperman G., Steenackers T., Aké Assi L., Holenz J., Bringmann G. 1997; In vitro inhibition of liver forms of the rodent malaria parasite Plasmodium berghei by naphthylisoquinoline alkaloids – structure-activity relationships of dioncophyllines A and C and ancistrocladine. Parasitol Res 83:673–679 [CrossRef]
    [Google Scholar]
17. Granthon A. C., Braga M. V., Rodrigues J. C., Cammerer S., Lorente S. O., Gilbert I. H., Urbina J. A., de Souza W. 2007; Alterations on the growth and ultrastructure of Leishmania chagasi induced by squalene synthase inhibitors. Vet Parasitol 146:25–34 [CrossRef]
    [Google Scholar]
18. Krauth-Siegel R. L., Meiering S. K., Schmidt H. 2003; The parasite-specific trypanothione metabolism of Trypanosoma and Leishmania . Biol Chem 384:539–549
    [Google Scholar]
19. Lefranc F., Facchini V., Kiss R. 2007; Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist 12:1395–1403 [CrossRef]
    [Google Scholar]
20. Menna-Barreto R. F., Salomão K., Dantas A. P., Santa-Rita R. M., Soares M. J., Barbosa H. S., de Castro S. L. 2009; Different cell death pathways induced by drugs in Trypanosoma cruzi : an ultrastructural study. Micron 40:157–168 [CrossRef]
    [Google Scholar]
21. Miranda K., Docampo R., Grillo O., Franzen A., Attias M., Vercesi A., Plattner H., Hentschel J., de Souza W. 2004; Dynamics of polymorphism of acidocalcisomes in Leishmania parasites. Histochem Cell Biol 121:407–418 [CrossRef]
    [Google Scholar]
22. Misra P., Khaliq T., Dixit A., Sen Gupta S., Samant M., Kumari S., Kumar A., Kushawaha P. K., Majumder H. K. other authors 2008; Antileishmanial activity mediated by apoptosis and structure-based target study of peganine hydrochloride dihydrate: an approach for rational drug design. J Antimicrob Chemother 62:998–1002 [CrossRef]
    [Google Scholar]
23. Moreno S. N., Docampo R. 2003; Calcium regulation in protozoan parasites. Curr Opin Microbiol 6:359–364 [CrossRef]
    [Google Scholar]
24. Natera S., Machuca C., Padrón-Nieves M., Romero A., Diaz E., Ponte-Sucre A. 2007; Proficiency of drug-resistant parasites. Int J Antimicrob Agents 29:637–642 [CrossRef]
    [Google Scholar]
25. Ouellette M., Drummelsmith J., Papadopoulou B. 2004; Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7:257–266 [CrossRef]
    [Google Scholar]
26. Ponte-Sucre A. 2003; Physiological consequences of drug resistance in Leishmania and their relevance for chemotherapy. Kinetoplastid Biol Dis 2:14 [CrossRef]
    [Google Scholar]
27. Ponte-Sucre A., Faber J. H., Gulder T., Kajahn I., Pedersen S. E. H., Schultheis M., Bringmann G., Moll H. 2007; Activity of naphthylisoquinoline alkaloids and synthetic analogs against Leishmania major . Antimicrob Agents Chemother 51:188–194 [CrossRef]
    [Google Scholar]
28. Ponte-Sucre A., Gulder T., Wegehaupt A., Albert C., Rikanović C., Schaeflein L., Frank A., Schultheis M., Unger M. other authors 2009; Structure-activity relationship and studies on the molecular mechanism of leishmanicidal N,C -coupled arylisoquinolinium salts. J Med Chem 52:626–636 [CrossRef]
    [Google Scholar]
29. Ramos H., Valdivieso E., Gamargo M., Dagger F., Cohen B. 1996; Amphotericin B kills unicellular Leishmania by forming aqueous pores permeable to small cations and anions. J Membr Biol 152:65–75 [CrossRef]
    [Google Scholar]
30. Shaha C. 2006; Apoptosis in Leishmania species and its relevance to disease pathogenesis. Indian J Med Res 123:233–244
    [Google Scholar]
31. Sieber M., Dekant W., Faber J. H., Bringmann G. 2006; Biotransformation and pharmacokinetics of the antiplasmodial naphthylisoquinoline alkaloid dioncophylline A. Xenobiotica 36:750–762 [CrossRef]
    [Google Scholar]
32. Sundar S., Chakravarty J. 2008; Paromomycin in the treatment of leishmaniasis. Expert Opin Investig Drugs 17:787–794 [CrossRef]
    [Google Scholar]
33. Sundar S., Chatterjee M. 2006; Visceral leishmaniasis – current therapeutic modalities. Indian J Med Res 123:345–352
    [Google Scholar]